Lakefront Biotherapeutics (GLPGF) Cash & Equivalents (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Cash & Equivalents for 14 consecutive years, with $78.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 31.2% year-over-year to $78.2 million in Q1 2026; TTM through Mar 2026 was $78.2 million, a 31.2% decrease from a year earlier, with the FY2025 full-year figure at $99.3 million, up 42.78% from the prior year.
• Cash & Equivalents was $78.2 million for Q1 2026 at Lakefront Biotherapeutics, down from $102.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.4 billion in Q1 2022 and troughed at $61.0 million in Q3 2024.
• A 5-year average of $236.3 million and a median of $102.3 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 90.54% in 2023 and jumped 49.0% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $518.4 million in 2022, then plunged by 65.38% to $179.5 million in 2023, then plunged by 61.75% to $68.6 million in 2024, then soared by 49.0% to $102.3 million in 2025, then decreased by 23.53% to $78.2 million in 2026.
• The last three Cash & Equivalents figures came in at $78.2 million (Q1 2026), $102.3 million (Q4 2025), and $75.4 million (Q3 2025), per Business Quant data.